Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies

Bone ◽  
2014 ◽  
Vol 68 ◽  
pp. 146-152 ◽  
Author(s):  
Frédéric Lézot ◽  
Julie Chesneau ◽  
Séverine Battaglia ◽  
Régis Brion ◽  
Beatriz Castaneda ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Zoledronic Acid ◽  
Pediatric Patients

My Patient Is Twitching; Could It Be Itching?

2020 ◽  
pp. 179-188
Author(s):  
Alexis Morvant ◽  
Emma Jones
Keyword(s):  
Adverse Effect ◽  
Palliative Care ◽  
Renal Disease ◽  
Pediatric Patients ◽  
Opioid Therapy ◽  
Chronic Health Conditions ◽  
Health Conditions ◽  
Opioid Antagonists ◽  
Distressing Symptom ◽  
Primary Mechanism

Pediatric patients receiving palliative care may experience itching as a distressing symptom for a wide variety of reasons. Antihistamine medications are widely used for treatment of this symptom and have effectiveness if histamine is the primary mechanism of itch. Pruritus is a known adverse effect of opioid therapy, occurring in 2–10% of patients. Opioid-induced pruritus is not primarily histamine related and therefore better treated by partial opioid antagonists. Chronic health conditions such as renal disease, cholestasis, and malignancy are all associated with pruritus. This chapter presents a broad differential for the symptom as well as a range of pharmacologic and nonpharmacologic therapies.

scholarly journals Safety & Efficacy of Cyclic Zoledronic Acid Therapy on Pediatric Secondary Osteoporosis

2015 ◽  
Vol 8 (8) ◽  
pp. 20
Author(s):  
Abdulmoein E. Al-Agha ◽  
Talal A. Shaikhain ◽  
Abdullah A. Ashour
Keyword(s):  
Zoledronic Acid ◽  
Children And Adolescents ◽  
Pediatric Patients ◽  
Systemic Disease ◽  
Laboratory Data ◽  
University Hospital ◽  
Secondary Osteoporosis ◽  
Fracture Rate ◽  
Acid Therapy ◽  
Positive Effects

<p class="NormalWeb"><strong>BACKGROUND/AIM:</strong> Osteoporosis is a systemic disease characterized by decreased bone density and increased tendency to develop fractures. Osteoporosis in children and adolescents is a rare disease usually secondary to Medical conditions or medications given to children. The condition affects normal bone growth and development and carries with it multiple morbidities (physical and psychological) if not corrected promptly. This study aims to share our experience with Zoledronic Acid Therapy in Pediatric patients with secondary osteoporosis.</p><p class="NormalWeb"><strong>METHOD:</strong> A retrospective study which included 46 patients aged 3 to 18 years. All patients received specific doses of Zoledronic acid and were followed up at King Abdulaziz University Hospital (KAUH) in Jeddah, Saudi Arabia. Clinical and laboratory data were collected for each patient from their files. Adverse events were also recorded.</p><p class="NormalWeb"><strong>RESULTS:</strong> The use of Zoledronic Acid in children and adolescents appears to be statically significant reduce fracture rate (p=0.005), bone turnover markers (Osteocalcin p= 0.003, CTX p= 0.008) and pain frequency in symptomatic individuals (p=0.000). Careful selection of cases is required to provide maximum benefits compared to risks associated with therapy.</p><p class="NormalWeb"><strong>CONCLUSION:</strong> This study demonstrates that Zoledronic acid has positive effects on clinical outcome and bone marker level as well as quality of life for Pediatric patients with Osteoporosis and their families, with no long-term side effects.</p>

scholarly journals Intravenous and Oral Paracetamol Have the Same Effect in Reducing Fever in Pediatric Patients

2020 ◽  
Vol 4 (3) ◽  
pp. 140
Author(s):  
Fitri Asymida ◽  
Yazid Dimyati ◽  
Bidasari Lubis ◽  
Aznan Lelo ◽  
Muhammad Ali ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Clinical Trial ◽  
Pediatric Patients ◽  
Intravenous Route ◽  
Open Label ◽  
Axillary Temperature ◽  
Antipyretic Effect ◽  
The Mean ◽  
Group 2 ◽  
Group 1

Background: The antipyretic effect of intravenous versus oral paracetamol is not well known. This study was aimed to compare the antipyretic effect of intravenous and oral paracetamol therapy to reduce fever.Materials and Methods: This was an open-label randomized clinical trial study. The subjects were children who presented to Pediatric Ward and Emergency of Haji Adam Malik Hospital, aged from 2 months to 18 years old, with axillary temperature ≥38.0ºC. Subjects were divided into two groups, group 1 received 15 mg/kg paracetamol intravenous and group 2 received the same dose of paracetamol but given through intravenous. The temperature reduction was analyzed by ANOVA, and the change in temperature was recorded at 0, 15, 30, 60, 120, and 180 minutes after drug administration.Results: In the first group, the mean temperature was decreased (p<0.001) from 15 to 180 minutes after the administration of paracetamol. Nausea was documented as the adverse effect for both oral and intravenous administration groups.Conclusion: The administration of 15 mg/kg paracetamol, either though intravenous or oral, have similar effect in reducing fever in children. Paracetamol therapy though intravenous route can be given if it cannot be given orally.Keywords: antipyretic, pediatrics, fever, intravenous, oral, paracetamol

Craniofacial consequences of high-dose zoledronic acid injections in onco-pediatric patients

2013 ◽  
Author(s):  
Frederic Lezot ◽  
Julie Chesneau ◽  
Severine Battaglia ◽  
Regis Brion ◽  
Jean-Christophe Farges ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Pediatric Patients ◽  
High Dose

scholarly journals Sequential Treatment Reduces the Acute Phases of Adverse Effect of Zoledronic Acid in First Time Users

2018 ◽  
Vol 08 (07) ◽  
pp. 189-205
Author(s):  
Jinmei Deng ◽  
Dongmei Cai ◽  
Suming Jie ◽  
Enjing Chen ◽  
Xiuzhen Cai ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Zoledronic Acid ◽  
Sequential Treatment ◽  
First Time

scholarly journals Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Motoki Isawa ◽  
Akiko Karakawa ◽  
Nobuhiro Sakai ◽  
Saki Nishina ◽  
Miku Kuritani ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Osteoblast Differentiation ◽  
Pediatric Patients ◽  
Root Formation ◽  
Biological Effects ◽  
Normal Growth ◽  
Bone Diseases ◽  
Bone Volume ◽  
Tooth Eruption ◽  
Tooth Root

AbstractThe anti-bone resorptive drugs denosumab, an anti-human-RANKL antibody, and zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, have recently been applied for treatment of pediatric patients with bone diseases, though details regarding their effects in growing children have yet to be fully elucidated. In the present study, we administered these anti-resorptive drugs to mice from the age of 1 week and continued once-weekly injections for a total of 7 times. Mice that received the anti-RANKL antibody displayed normal growth and tooth eruption, though osteopetrotic bone volume gain in long and alveolar bones was noted, while there were nearly no osteoclasts and a normal of number osteoblasts observed. In contrast, ZOL significantly delayed body growth, tooth root formation, and tooth eruption, with increased osteoclast and decreased osteoblast numbers. These findings suggest regulation of tooth eruption via osteoblast differentiation by some types of anti-resorptive drugs.

Sign in / Sign up

Export Citation Format

Share Document